Microdosing Surveys: What They Report

Microdosing surveys what they report is a question more people are asking as interest in sub-perceptual dosing grows. A microdosing survey is a large-scale questionnaire — a type of observational research tool that gathers self-reported data on why people microdose, what substances they use, what benefits they perceive, and what adverse effects they encounter. This guide on microdosing surveys what they report is written for adults interested in reading the survey data critically. According to Rosenbaum et al. (2020), the majority of published microdosing evidence still comes from observational surveys rather than controlled trials, meaning the findings tell you what people report — not necessarily what the substance caused.

Below you'll find the primary data table summarising the largest surveys published to date, followed by sections explaining what each column actually means, where the gaps are, and how to interpret these numbers without fooling yourself.

Major Microdosing Survey Data at a Glance

The largest microdosing surveys have collectively gathered data from over 12,000 respondents, though sample quality varies enormously between studies.

What Surveys Actually Measure (and What They Don't)

Microdosing surveys measure self-reported perceptions of benefit and harm — not objective pharmacological effects. Every survey in that table shares a structural limitation: respondents self-select. People who had a bad time microdosing and stopped after a week are less likely to fill in a 40-minute questionnaire about microdosing. People who are enthusiastic about it are more likely. This introduces what researchers call "selection bias," and it inflates positive reports.

According to Lea et al. (2020), adults who microdose psychedelics report lower levels of depression and anxiety compared to non-microdosers — but the study's cross-sectional design cannot tell you whether microdosing reduced their depression or whether less-depressed people are more likely to microdose in the first place. The arrow of causation is invisible in survey data.

What surveys can do well: identify patterns of use, catalogue the range of reported effects (both positive and negative), and flag safety signals that deserve controlled investigation. They're a starting point, not a conclusion. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has similarly noted in its 2024 European Drug Report that self-report data on novel psychoactive substance use requires cautious interpretation due to these inherent methodological constraints. The MAPS (Multidisciplinary Association for Psychedelic Studies) organisation has also emphasised the need for controlled trials to supplement survey-level evidence.

Why People Say They Microdose

Mood improvement is the single most cited motivation across every major microdosing survey, reported by roughly 40–50% of respondents.

AZARIUS · Why People Say They Microdose

Across every major survey, the top three motivations are remarkably consistent:

1. Mood improvement / reducing depression and anxiety — cited by roughly 40–50% of respondents in most samples
2. Cognitive enhancement — focus, creativity, and problem-solving, cited by 20–35%
3. General well-being and self-development — a vaguer category that captures 15–25%

Less prominent motivations include reducing substance use (alcohol, tobacco), managing chronic pain, and curiosity. Kuypers et al. (2019) noted that respondents with mental health concerns were significantly overrepresented compared to the general population — suggesting that microdosing attracts people who are already looking for relief.

A 2019 commentary in the Journal of Psychopharmacology (Kuypers et al.) clarified that "microdosing" in the psychedelic community means something specific: roughly 1/10th to 1/20th of a standard dose, taken on a schedule (typically every third day), with the explicit intention of sub-perceptual effects. This is different from the pharmacological use of "microdose" in drug development, where it refers to sub-therapeutic doses used for pharmacokinetic testing.

Substances and Products Commonly Referenced

In the Netherlands, where psilocybin truffles are legally available, many survey respondents report using truffle-based preparations. Those looking to buy psilocybin truffles for microdosing often choose products like the Microdosing XP Truffles pack or the Fresh Microdosing Truffles available at Azarius. Precision scales — such as the On Balance Myco digital scale — are frequently mentioned in survey free-text responses as essential for consistent dosing. If you want to get started with growing your own supply, mushroom grow kits are another option respondents mention, though dose standardisation becomes more difficult with home-grown material.

The Adverse Effects Column

Roughly 1 in 4 microdosers report at least one undesired effect per year, according to the largest survey to date. The positive reports get the headlines, but the adverse-effects data is arguably more useful for anyone actually considering microdosing. According to Lea et al. (2020), about 1 in 4 microdosers reported at least one undesired effect in the past year, and roughly 10% described their experience as genuinely adverse.

AZARIUS · The Adverse Effects Column

Commonly reported issues across surveys:

• Physiological discomfort — nausea, headaches, jaw tension, insomnia (5–8%)
• Mood disturbance — increased anxiety on dose days, irritability, emotional instability (4–7%)
• Cognitive fog — difficulty concentrating, feeling "off" rather than sharp (3–5%)
• Heart-related concerns — a less-reported but theoretically significant flag, since psilocybin and LSD both activate 5-HT2B receptors, which are implicated in cardiac valvulopathy with chronic stimulation (Roth, 2007)

The 5-HT2B concern is worth flagging specifically. No survey has documented actual valvular heart disease in microdosers — the exposure duration and receptor affinity may not reach the threshold seen with fenfluramine or methysergide. But the data simply doesn't exist yet to rule it out for long-term (12+ month) microdosing schedules. This remains an open question that no survey can answer; it requires echocardiographic follow-up studies.

For comparison, consider caffeine — a substance most people consider benign. Surveys of daily coffee drinkers routinely find that 20–30% report at least one undesired effect (jitteriness, insomnia, digestive upset), yet few would call coffee "dangerous." The microdosing adverse-effect rates sit in a similar range, but the substances involved are far less studied over long durations, which makes the comparison useful for calibration but not for reassurance.

The Placebo Problem: Szigeti et al. (2021)

The placebo group improved just as much as the microdose group in the largest self-blinding study to date. The largest placebo-controlled microdosing study to date wasn't run in a lab — it was citizen science. Szigeti et al. (2021) recruited participants who were already microdosing and asked them to self-blind using opaque capsules: some contained their microdose, some were empty placebos. Participants didn't know which was which on any given day.

The result: both the microdose group and the placebo group showed statistically significant improvements in well-being, mindfulness, and life satisfaction over the study period. The microdose group did not outperform the placebo group on any primary outcome measure.

This doesn't prove microdosing "does nothing." It proves that expectation — believing you've taken a microdose — produces measurable psychological improvements. Whether there's an additional pharmacological effect hiding underneath the placebo response is something that 191 completers cannot definitively answer. Larger, lab-controlled trials are needed.

What is citizen science in this context? It's a study design where participants act as both subjects and experimenters, following a protocol designed by researchers but executing it at home with their own substances. It's clever and scalable, but introduces variables (dose accuracy, adherence, substance purity) that a clinical lab would control.

How to Read These Findings Without Fooling Yourself

The single most important skill is checking whether the study has a control group — most microdosing surveys do not. If you're reading microdosing survey data — whether in a news article, a Reddit thread, or a peer-reviewed paper — here's a practical framework:

AZARIUS · How to Read These Findings Without Fooling Yourself

1. Check the study design. Cross-sectional surveys (one-time questionnaires) cannot establish causation. Prospective longitudinal designs (following people over time) are better but still lack controls. Only placebo-controlled trials can isolate the drug effect from expectation.
2. Look at the denominator. "85% of respondents reported improved mood" sounds impressive until you realise 85% of people who chose to keep microdosing and then fill in a survey about it reported improved mood. That's survivorship bias in action.
3. Check for a control group. Lea et al. (2020) compared microdosers to non-microdosers, which is useful but not the same as random assignment. The groups may differ in dozens of unmeasured ways (income, exercise habits, therapy access, personality traits).
4. Note the substance and dose. "Microdosing" in surveys covers everything from 5µg LSD to 0.3g dried psilocybin mushrooms to truffle preparations of unknown potency. These are not interchangeable. Psilocybin content varies 2–4x between mushroom species and even between flushes of the same grow kit.
5. Read the adverse-effects section. It's usually buried. Dig it out. A 25% adverse-effect rate (Lea et al., 2020) is not trivial, even if most effects were mild.
6. Ask: "Would I be in this sample?" Most survey respondents are male, educated, in their 20s–40s, from Western countries, and already experienced with psychedelics. If that's not you, the findings may not generalise to your situation.

What No Survey Can Answer

No survey — regardless of sample size — can confirm whether microdosing is pharmacologically active at the doses people typically use. Surveys are good at generating hypotheses. They are bad at confirming them. Specifically, no survey — no matter how large — can tell you:

• Whether microdosing is pharmacologically active at the doses people use (as opposed to a well-maintained placebo effect supported by ritual and expectation)
• Whether long-term microdosing is safe for your heart (the 5-HT2B question)
• What the optimal dose, frequency, or substance is for any specific outcome
• Whether the benefits persist after stopping, or disappear within days

These questions require randomised controlled trials, and as of early 2026, only a handful have been completed — most with small samples and short durations. The Beckley Foundation has been among the organisations pushing for more rigorous clinical microdosing research, including dose-finding studies that could finally establish whether sub-perceptual doses produce measurable neurological changes distinct from placebo. The field is moving, but it hasn't arrived.

The 2025 RAND Survey: What's New

The RAND survey is the first microdosing survey to use a probability-based, nationally representative sample rather than recruiting from psychedelic communities. The first report from the 2025 RAND Psychedelics Survey is notable because it uses a probability-based, nationally representative U.S. panel — a significant methodological upgrade over convenience samples recruited through psychedelic forums. This means the respondents weren't self-selected enthusiasts; they were drawn to represent the general population.

Full results are still being published, but the preliminary data confirms that microdosing has moved well beyond the Silicon Valley biohacker stereotype. The demographics are broader than earlier surveys suggested, and the motivations remain consistent: mood, focus, and general well-being dominate. Whether this larger, more representative sample will show the same effect sizes as earlier convenience samples remains to be seen — and that's exactly the kind of question a representative survey can help answer.

Microdosing Surveys vs. Clinical Trials: A Quick Comparison

Microdosing surveys and clinical trials answer fundamentally different questions — surveys tell you what people experience in the wild, while trials tell you what a substance does under controlled conditions. Here's how they stack up:

Both approaches are necessary. Surveys generate the hypotheses; trials test them. The microdosing field currently has an abundance of the former and a shortage of the latter.

What We Don't Know (An Honest Assessment)

We want to be straightforward about the limits of this guide. We've summarised the microdosing surveys as accurately as we can, but we're a smartshop — not a research lab. We sell psilocybin truffles and related products, which means we have a commercial interest in this topic. We've tried to let the data speak and to highlight the adverse effects and placebo findings as prominently as the positive reports, but you should read us with the same critical eye you'd apply to any source with skin in the game. The honest truth is that the science of microdosing is still in its early chapters, and anyone — us included — who tells you the story is finished is getting ahead of the evidence.

Last updated: April 2026